Skip to main content

Table 2 Mixed model analysis of pCRA progression with different treatment groups

From: Long-term outcomes of anti-vascular endothelial growth factor therapy with and without posterior scleral reinforcement on myopic maculopathy in myopic choroidal neovascularization eyes

 

Perilesional CRA (mm2)

 

Patchy Extralesional CRA (mm2)

Beta (95% CI)

P

 

Beta (95% CI)

P

Baseline

0.00 (-0.21, 0.20) a

0.9775

 

0.70 (0.50, 0.89)

< 0.0001

Change of 12-month

0.01 (-0.39, 0.41)

0.9589

 

0.06 (-0.34, 0.22)

0.6864

Change of 24-month

0.14 (-0.28, 0.57)

0.4948

 

0.26 (-0.10, 0.62)

0.1497

Treatment group

     

 Group B

Reference

  

Reference

 

 Group A

0.57 (0.01, 1.13)

0.048

 

0.21 (-0.17, 0.59)

0.2716

  1. a Estimated beta less than 0.01.
Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us